Continuous tracking captures market inflection points, seasonal patterns, and emerging disruptions that point-in-time studies miss, transitioning research from a one-off engagement into a strategic partnership
Semaglutide es un agonista del receptor GLP-1 aprobado para diabetes tipo 2 y manejo del peso segn formulacin Reduce significativamente la albuminuria y puede desacelerar la progresin de enfermedad renal diabtica El riesgo principal es lesin renal aguda secundaria a deshidratacin por efectos gastrointestinales Requiere monitoreo de funcin renal especialmente en pacientes con ERC preexistente o edad avanzada No requiere ajuste de dosis por funcin renal pero precaucin en eGFR 300 mg/g): Cada 3-6 meses Es crucial realizar monitoreo adicional durante perodos de mayor riesgo, como despus de iniciar semaglutide o despus de aumentos de dosis, particularmente en pacientes con insuficiencia renal preexistente o cuando ocurren efectos gastrointestinales significativos
The challenge in evaluating GLP-1 safety lies in disentangling drug effects from underlying disease risk
In contrast, similar expression levels of MTTP and apoB100 between patients with steatosis, NASH, and healthy controls have also been reported, denoting the considerable disease heterogeneity associated with NAFLD [124]
In humans, a Mediterranean diet rich in olive oil led to higher post-meal GLP-1 levels, improved insulin sensitivity, and lower fasting and post-meal blood glucose levels compared to a diet high in saturated fats
